Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nexien BioPharma, Inc. (NXEN)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
4340 East Kentucky Avenue 80246
Glendale, CO, US
Glendale, CO, US
CEO
Richard S. Greenberg
Website
nexienbiopharma.com
IPO
2017-11-29
CIK 1625288 ISIN US65343D1000
Description
Nexien BioPharma, Inc., a pharmaceutical firm headquartered in Glendale, Colorado, concentrates its efforts on the research, advancement, and market introduction of cannabinoid-derived medications. The company utilizes both pre-clinical and clinical development paths to address a variety of diseases, medical conditions, and disorders. It adopted its current name in September 2018, having previously operated as Intiva BioPharma Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
535
Beta
-0.84
Float Shares
31.27M
Free Float %
44.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -98.97% | -99.75% | -99.88% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
-2,078.63
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+37.9% ★ Q1'25: +50.0% (vs Q1'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'25: +68.6% (vs Q1'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+6.2% Q1'25: +6.6% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-926.57×
Valuation Multiples
From
To
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jeffrey Friedland | 26.27M | 60.30% | 2.00M | 24.27M | 2.00M | 10.00 | IN | USA | 2017-12-01 | ↗ |
| 2 | Richard S. Greenberg | 24.80M | 57.00% | 800.0K | 24.00M | 800.0K | 10.00 | IN | UNITED STATES | 2017-12-01 | ↗ |
| 3 | Intiva USA Inc. | 24.00M | 55.20% | — | 24.00M | — | 10.00 | CO | Colorado, USA | 2017-12-01 | ↗ |
| 4 | Alain D. Bankier | 2.28M | 5.20% | 2.28M | — | 2.28M | — | IN | United States | 2018-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
500.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+500,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-23 | Wasoff Evan L | Officer | A-Award | A | Common stock | 2,000,000 | 0.00 | — | 6,500,000 | — | ↗ |
| 2024-05-23 | Greenberg Richard S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 7,185,193 | — | ↗ |
| 2023-10-31 | Wasoff Evan L | Officer | A-Award | A | Common stock | 250,000 | 0.00 | — | 4,500,000 | — | ↗ |
| 2023-10-31 | Greenberg Richard S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 250,000 | 0.00 | — | 6,185,193 | — | ↗ |
| 2023-07-25 | Wasoff Evan L | Officer | A-Award | A | Common stock | 250,000 | 0.00 | — | 4,250,000 | — | ↗ |
| 2023-07-25 | Greenberg Richard S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 250,000 | 0.00 | — | 5,935,193 | — | ↗ |
| 2023-07-25 | Goldfarb Robert I | Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 2,278,000 | — | ↗ |
| 2023-04-01 | Wasoff Evan L | Officer | A-Award | A | Common stock | 250,000 | 0.00 | — | 4,000,000 | — | ↗ |
| 2023-04-01 | Greenberg Richard S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 250,000 | 0.00 | — | 5,685,193 | — | ↗ |
| 2023-04-01 | Goldfarb Robert I | Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 2,028,000 | — | ↗ |
| 2023-01-17 | Wasoff Evan L | Director / Officer | A-Award | A | Common stock | 250,000 | 0.00 | — | 3,750,000 | — | ↗ |
| 2023-01-17 | Greenberg Richard S | Director / Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 5,435,193 | — | ↗ |
| 2023-01-17 | Goldfarb Robert I | Director / Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 1,778,000 | — | ↗ |
| 2022-10-17 | Wasoff Evan L | Director / Officer | A-Award | A | Common stock | 250,000 | 0.00 | — | 3,500,000 | — | ↗ |
| 2022-10-17 | Greenberg Richard S | Director / Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 5,185,193 | — | ↗ |
| 2022-10-17 | Goldfarb Robert I | Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 1,528,800 | D | ↗ |
| 2022-07-27 | Wasoff Evan L | Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 3,250,000 | — | ↗ |
| 2022-07-27 | Greenberg Richard S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 250,000 | 0.00 | — | 4,935,193 | — | ↗ |
| 2022-07-27 | Goldfarb Robert I | Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 1,278,800 | D | ↗ |
| 2022-04-20 | Wasoff Evan L | Officer | A-Award | A | Common stock | 250,000 | 0.00 | — | 3,000,000 | — | ↗ |
| 2022-04-20 | Greenberg Richard S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 250,000 | 0.00 | — | 4,685,193 | — | ↗ |
| 2022-01-27 | Wasoff Evan L | Officer | A-Award | A | Common stock | 250,000 | 0.00 | — | 2,750,000 | — | ↗ |
| 2022-01-27 | Greenberg Richard S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 250,000 | 0.00 | — | 4,435,192 | — | ↗ |
| 2021-11-29 | Wasoff Evan L | Officer | A-Award | D | Common stock | 500,000 | 0.00 | — | 2,500,000 | — | ↗ |
| 2021-11-29 | Greenberg Richard S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 500,000 | 0.00 | — | 4,185,192 | — | ↗ |
| 2021-06-07 | Snider Lindy | Director | A-Award | A | Common stock | 250,000 | 0.00 | — | 730,000 | — | ↗ |
| 2021-04-01 | Wasoff Evan L | Officer | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 2,000,000 | — | ↗ |
| 2021-04-01 | Greenberg Richard S | Director / Officer / 10% Owner | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 3,685,192 | — | ↗ |
| 2020-11-24 | Greenberg Richard S | Director / Officer / 10% Owner | A-Award | A | Class B Warrant | 1,062,953 | 0.04 | 46.0K | 1,062,953 | — | ↗ |
| 2020-08-19 | Wasoff Evan L | Officer | A-Award | A | Options to purchase common stock (right to buy) | 1,500,000 | 0.08 | 120.0K | 1,500,000 | — | ↗ |
| 2020-08-19 | Greenberg Richard S | Director / Officer | A-Award | A | Stock option - right to buy | 2,500,000 | 0.08 | 200.0K | 2,500,000 | — | ↗ |
| 2020-08-19 | Goldfarb Robert I | Director / Officer | A-Award | A | Options to purchase common stock (right to buy) | 1,000,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2020-08-12 | Greenberg Richard S | Director / Officer | C-Conversion | A | Common Stock | 1,797,192 | 0.01 | 25.2K | 2,685,192 | — | ↗ |
| 2019-11-22 | Friedland Jeffrey | — | G-Gift | D | Common Stock | 228,800 | 0.00 | — | 0 | — | ↗ |
| 2019-04-04 | Kanativa USA Inc. | 10% Owner | S-Sale | D | Common Stock | 5,000,000 | 0.09 | 425.0K | 19,000,000 | — | ↗ |
| 2019-04-04 | Kanativa Inc. | 10% Owner | S-Sale | D | Common Stock | 5,000,000 | 0.09 | 425.0K | 19,000,000 | — | ↗ |
| 2019-04-04 | Friedland Jeffrey | — | S-Sale | D | Common Stock | 5,000,000 | 0.09 | 425.0K | 19,000,000 | — | ↗ |
| 2019-04-01 | Bankier Alain D | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-10-26 | Wasyl Alexander Michael | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 5,445,000 | — | ↗ |
| 2018-10-26 | Wasoff Evan L | Officer | A-Award | A | Stock option - right to buy | 200,000 | 0.66 | 131.0K | 200,000 | — | ↗ |
| 2018-10-26 | Reeh Jeremy Robert | Officer | — | D | Common Stock | 0 | 0.00 | — | 1,925,000 | — | ↗ |
| 2018-10-26 | Manganella Frank J | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,420,000 | — | ↗ |
| 2018-10-26 | Greenberg Richard S | Director / Officer | A-Award | A | Options to purchase common stock (right to buy) | 100,000 | 0.66 | 65.5K | 100,000 | — | ↗ |
| 2018-10-26 | Bankier Alain D | Director / Officer | A-Award | A | Stock options (right to buy) | 500,000 | 0.66 | 327.5K | 500,000 | — | ↗ |
| 2018-10-26 | Aceto Joseph F | Officer | — | D | Common Stock | 0 | 0.00 | — | 1,045,000 | — | ↗ |
| 2018-10-01 | Bankier Alain D | Director / Officer | A-Award | A | Stock options (right to buy) | 500,000 | 0.48 | 240.0K | 500,000 | — | ↗ |
| 2018-08-10 | Clark Courtney Lynne | Director | — | D | common stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-08 | Snider Lindy | Director | J-Other | A | Class D Warrants (right to buy) | 40,000 | 1.00 | 40.0K | 40,000 | — | ↗ |
| 2018-08-08 | Goldfarb Robert I | Officer | J-Other | A | Class D Warrants (right to buy) | 2,400 | 1.00 | 2.4K | 2,400 | — | ↗ |
| 2018-08-06 | Bankier Alain D | Director / Officer | J-Other | D | Class C Warrants (right to buy) | 28,000 | 0.50 | 14.0K | 0 | — | ↗ |
| 2018-07-25 | Wasoff Evan L | Officer | A-Award | A | Stock options (right to buy) | 420,000 | 0.54 | 226.8K | 420,000 | — | ↗ |
| 2018-07-25 | Snider Lindy | Director | A-Award | A | Stock option - right to buy | 100,000 | 0.54 | 54.0K | 100,000 | — | ↗ |
| 2018-07-25 | Greenberg Richard S | Director / Officer / 10% Owner | A-Award | A | Stock option - right to buy | 150,000 | 0.54 | 81.0K | 150,000 | — | ↗ |
| 2018-07-25 | Bankier Alain D | Director / Officer | A-Award | A | Stock option - right to buy | 840,000 | 0.54 | 453.6K | 840,000 | — | ↗ |
| 2018-06-28 | Greenberg Richard S | Director / Officer / 10% Owner | X-InTheMoney | A | Common Stock | 88,000 | 0.38 | 33.4K | 888,000 | — | ↗ |
| 2018-06-27 | Greenberg Richard S | Director / Officer / 10% Owner | J-Other | A | Class B Warrants (right to buy) | 88,000 | 0.38 | 33.4K | 88,000 | — | ↗ |
| 2018-06-19 | Snider Lindy | Director | X-InTheMoney | D | Class B Warrants (right to buy) | 40,000 | 0.38 | 15.2K | 0 | — | ↗ |
| 2018-05-15 | Bankier Alain D | Director / Officer | X-InTheMoney | A | Common Stock | 28,000 | 0.38 | 10.6K | 2,256,000 | — | ↗ |
| 2018-05-05 | Goldfarb Robert I | Officer | X-InTheMoney | A | Common Stock | 2,400 | 0.38 | 912.00 | 1,028,800 | — | ↗ |
| 2018-03-08 | Friedland Jeffrey | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-01-26 | Snider Lindy | Director | — | D | Common Stock | 0 | 0.00 | — | 440,000 | — | ↗ |
| 2018-01-16 | Friedland Jeffrey | Director / Officer / 10% Owner | L-Small | A | Common Stock | 20,800 | 0.25 | 5.2K | 228,800 | — | ↗ |
| 2018-01-12 | Goldfarb Robert I | Officer | L-Small | A | Common stock | 2,400 | 0.25 | 600.00 | 1,026,400 | — | ↗ |
| 2018-01-12 | Bankier Alain D | Director | L-Small | A | Common Stock | 28,000 | 0.25 | 7.0K | 2,228,000 | — | ↗ |
| 2017-11-29 | Wasoff Evan L | Officer | J-Other | A | Common Stock | 629,128 | 0.00 | — | 1,000,000 | — | ↗ |
| 2017-11-29 | Snider Lindy | Director | — | D | Class C Warrants (right to buy) | 40,000 | 0.50 | 20.0K | 0 | — | ↗ |
| 2017-11-29 | Intiva USA Inc | 10% Owner | J-Other | A | Common Stock | 15,099,083 | 0.00 | — | 24,000,000 | — | ↗ |
| 2017-11-29 | Greenberg Richard S | Director / Officer / 10% Owner | J-Other | A | Common Stock | 503,303 | 0.00 | — | 800,000 | — | ↗ |
| 2017-11-29 | Goldfarb Robert I | Officer | J-Other | A | Class A Warrants (right to buy) | 2,400 | 0.25 | 600.00 | 2,400 | — | ↗ |
| 2017-11-29 | Friedland Jeffrey | Director / Officer / 10% Owner | J-Other | A | Class C Warrants (right to buy) | 20,800 | 0.50 | 10.4K | 20,800 | — | ↗ |
| 2017-11-29 | Bankier Alain D | Director | J-Other | A | Common Stock | 1,384,083 | 0.00 | — | 2,200,000 | — | ↗ |
| 2017-10-13 | Wasoff Evan L | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,225,229 | — | ↗ |
| 2017-10-13 | Intiva USA Inc | 10% Owner | J-Other | D | Common Stock | 20,000,000 | 0.00 | — | 0 | — | ↗ |
| 2017-10-13 | Greenberg Richard S | Director / Officer / 10% Owner | J-Other | A | Common Stock | 1,780,183 | 0.00 | — | 1,780,183 | — | ↗ |
| 2017-10-13 | Goldfarb Robert I | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,278,635 | — | ↗ |
| 2017-10-13 | Friedland Jeffrey | Director / Officer / 10% Owner | J-Other | A | Common Stock | 53,405,501 | 0.00 | — | 53,405,501 | — | ↗ |
| 2017-10-13 | Bankier Alain D | Director | — | D | Common Stock | 0 | 0.00 | — | 4,895,504 | — | ↗ |
| 2017-06-26 | Intiva USA Inc | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 20,000,000 | — | ↗ |
| 2017-06-26 | Greenberg Richard S | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 20,000,000 | — | ↗ |
| 2017-06-26 | Friedland Jeffrey | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 20,000,000 | — | ↗ |
| 2015-01-13 | Heiden Ivo | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 10,000,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
70.77M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert I. Goldfarb | Chief Operating Officer | 55.0K | male |
| Evan L. Wasoff | Chief Financial Officer | — | male |
| Richard S. Greenberg | Founder, Chief Executive Officer, Executive Vice President & Chairman | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NXEN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
